NCT07227194Completed
Machine Learning Assessment of Next-Day Migraine Likelihood
Machine Learning Assessment Of Next-Day Migraine Likelihood Collected Via The Nerivio App
Source: ClinicalTrials.gov · Last updated 12 Nov 2025
Brief summary (registry, in English)
Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application used for migraine treatment by the Remote Electrical Neuromodulation (REN) wearable device.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 53065 (actual)
- First submitted
- 9 Nov 2025
- Start date
- Feb 2025
- Primary completion date
- Aug 2025
- Lead sponsor
- Theranica
- Diseases
- Migraine
- NCT number
- NCT07227194
What you commit to
- Study type: Observational
- Participants enrolled: 53065
- From Feb 2025 to the primary completion date, Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- NA
Who the study is looking for
- \- Nerivio users age 8 and above.
- \- Filled at least 2 daily diaries/ pre-treatment reports via the Nerivio app during the same month.
Age in the registry: 8 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Theranica USA Inc Coordinator of this site? Confirm its status | Bridgewater | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.